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 Thrombolysis with alteplase after stroke: extending outcomes
In their ﬁ rst report1 since publication of the main 
results,2,3 the third International Stroke Trial (IST-3) 
investigators provide new data on the eﬀ ects of 
alteplase on health outcomes after stroke, and so re-
ignite debate about the best time and method to assess 
recovery.
90 days is the gold standard time for assessing 
the eﬀ ects of treatment in acute stroke trials. This 
window provides a compromise between timely 
assessment of adverse eﬀ ects and physical recovery 
and avoidance of the additional costs and logistic 
diﬃ  culties of longer follow-up. 18 month follow-up 
in the IST-3 study has several beneﬁ ts. First, ﬁ nding 
no diﬀ erence in overall mortality (35%) between the 
groups provides reassurance that alteplase has no 
long-term adverse consequences related to restenosis 
of incompletely recanalised intracerebral arterioles. 
However, the data also suggest that any reduced 
neurological deﬁ cit from treatment did not translate 
into a net improvement in medium-term survival. 
Second, at 18 months, the proportion of patients 
who were alive and independent was signiﬁ cantly 
higher in the alteplase group compared with the 
control group (adjusted odds ratio [OR] 1·28, 95% CI 
1·03–1·57; p=0·024). This diﬀ erence was not evident in 
either the full cohort (1·13, 0·95–1·35; p=0·181)2 or at 
6 months in the participants who were followed up for 
18 months (1·18, 0·97–1·45; p=0·10).1 The consistent 
between-group distribution of scores on the Oxford 
handicap scale at 6 months and 18 months suggests 
that the treatment eﬀ ect was stable but also shows 
some limitations to the approach.
The Oxford handicap scale score is based on several 
broad, ordered levels and so it is somewhat insensitive 
to change over time, can exhibit ceiling or ﬂ oor eﬀ ects, 
and is limited in its assessment of the functional 
consequences of stroke on the lives of those aﬀ ected. 
As a result, health-related quality of life measures are 
recognised as valid and useful additional endpoints 
in randomised controlled trials, particularly for 
treatments that target chronic or disabling diseases. 
Indeed, medical decision-making increasingly focuses 
on health-related quality of life as an important 
variable because many treatments do not cure disease 
and patients often have an active role in their medical 
care and are particularly interested in the non-clinical 
aspects of treatment and their future requirement for 
care. EuroQoL is a popular generic, preference-based, 
measure of health-related quality of life because it is 
simple, concise, and eﬃ  cient; it is also able to convert 
health eﬀ ects into quality-adjusted life-years for 
evaluations of cost-eﬀ ectiveness.
The large sample size in the IST-3 study (2348 patients 
assessed at 18 months) overcomes potential biases 
introduced through the use of proxies (in 54% of 
patients) to assess health-related quality of life. The 
ﬁ ndings from the EuroQoL instrument are therefore not 
only robust, but also oﬀ er separate conﬁ rmation of the 
functional beneﬁ ts of alteplase besides the results of the 
Oxford handicap scale score. Additionally, they show 
that recovery from ischaemic stroke continues beyond 
6 months—in the patients followed up at 18 months, 
only ability to self-care and ability to do usual activities 
were signiﬁ cantly improved at 6 months in the alteplase 
group. The diﬀ erence between groups in overall 
health utility score also increased between 6 months 
and 18 months (from 0·04 to 0·06). Although this 
change is small, scores ranging from as little as –0·01 
to 1·4 are still clinically meaningful.4,5 Finally, half of 
all participants reported at least a moderate degree of 
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One of the most frustrating aspects of treating people 
with epilepsy is the inability to predict who will respond 
to antiepileptic drugs and who will be treatment 
resistant. Many theories of treatment resistance have 
been proposed, including association with disease 
severity and cause, genetic predisposition, changes in 
drug targets in the brain, aberrant drug metabolism, and 
even previous drug exposures during epileptogenesis,1–3 
all of which could contribute to drug response. Whatever 
the cause, an individual who has shown resistance to 
one antiepileptic drug at a reasonable dose has a high 
likelihood of showing resistance to multiple drugs. In a 
study of 1098 newly diagnosed patients, failure of the 
ﬁ rst antiepileptic drug, at 50% or more of the WHO-
deﬁ ned daily dose, predicted pharmacoresistance in 
more than 70% of patients.4 
Upregulation of P-glycoprotein is one mechanism that 
might account for resistance to multiple antiepileptic 
drugs. Since many such drugs are substrates of 
P-glycoprotein, including commonly used treatments 
such as phenytoin, phenobarbital, lamotrigine, 
levetiracetam, topiramate, and carbamazepine-epoxide, 
the overexpression of P-glycoprotein could account 
for multidrug-resistance. In this issue of The Lancet 
Neurology, Maria Feldmann and colleagues5 provide the 
ﬁ rst in-vivo human evidence of the association between 
P-glycoprotein overactivity and pharmacoresistance 
in temporal lobe epilepsy. This was accomplished 
by looking at diﬀ erences in PET studies with the 
P-glycoprotein substrate (R)-[11C]verapamil (and in 
some cases comparing before-and-after infusion of 
the P-glycoprotein inhibitor tariquidor) in 14 patients 
with pharmacoresistant temporal lobe epilepsy, eight 
seizure-free patients, and 13 healthy controls, and 
showing that the treatment-resistent patients had 
apparent higher baseline P-glycoprotein activity focally 
in regions of the hippocampus and temporal lobe. 
Upregulation of P-glycoprotein potentially ﬁ ts into 
many of the hypotheses to explain drug-resistance. 
There has been speculation that some individuals 
might have a genetic predisposition for increased 
expression of P-glycoprotein, due to a polymorphism 
in ABCB1, the P-glycoprotein transporter gene,6 which 
could lead to pharmacoresistance. However, as long as 
this overexpression occurs thoughout the CNS, these 
individuals might also be expected to have resistance 
to side-eﬀ ects involving the CNS, since less of the 
drug would reach its target. A second scenario is that 
some causes of epilepsy also produce an upregulation 
of P-glycoprotein, and in this case upregulation could 
depression or anxiety during follow-up, emphasising 
the importance of this comorbidity in adjusting to the 
eﬀ ects of stroke.6,7  
I commend the IST-3 investigators for providing 
a more comprehensive, patient-centred approach 
to assessment of the eﬀ ects of alteplase on quality 
of life than has previously been done. As shown in 
INTERACT2,8 assessment of health-related quality of 
life helps the interpretation of outcomes and is an 
important part of decision-making about eﬃ  cacy of 
treatment that accounts for the patients’ perspective.
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